The Child Health Institute of New Jersey (CHINJ) was established in 1998 by the Robert Wood Johnson Medical School with the mission to advance basic science knowledge of vertebrate development and growth, and mechanisms of human diseases. The CHINJ is part of a larger biomedical research program that includes the neighboring Bristol-Myers Squibb Children's Hospital at Robert Wood Johnson University Hospital, PSE&G Children's Specialized Hospital, The Cancer Institute of New Jersey and the soon-to-be-established The Cardiovascular Institute of New Jersey.

Completed in September 2005, the CHINJ building is located on the New Brunswick campus and includes 40,000 sq. ft. of open laboratory design and office space and a 25,000 sq. ft. mouse barrier facility, in addition to core laboratories for mouse gene targeting and transgenesis, histology/pathology, imaging, and microarray analysis. The Institute has initiated research programs in basic and translational research in childhood diseases and is recruiting world-class investigators in the areas of immunity, autoimmunity and inflammation, autism and neurodevelopment, pediatric cancers and stem cells, and obesity, metabolism and genetics.

Congratulations to Zhiping Pang, M.D., Ph.D. for his new grant award:

“Regulation of MeCP2 by chromosome21- microRNAs and the implications in intellectual disability” from The Jerome Lejeune Foundation. 

Dr. Pang’s grant will examine the possible role changes in dosage and levels of chromosome 21-encoded microRNAs in affecting intellectual development in children with Down Syndrome.  The Jerome Lejeune Foundation is the world’s oldest and largest private funder of research into treatments for intellectual disabilities of genetic origin, especially, but not limited to Down Syndrome.